Has Samer Kasbari, MD received payments from drug or device companies?

Yes. Drug and device makers reported $497,904 in general payments to Samer Kasbari, MD across 359 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Samer Kasbari, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Samer Kasbari, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Samer Kasbari, MD

Hematology & Oncology · Goldsboro, NCNPI 1881702595

Payments from drug & device makers

$497,904in general payments, 2019–2025

Across 359 payments — averaging $1386.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$355K
Amgen$111K
Janssen Research & Development, LLC$11K
Sanofi$9K
Lilly USA, LLC$3K
Novartis$3K
plus $6K from 52 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	119	$355,456
Amgen	2	$111,455
Janssen Research & Development, LLC	9	$10,897
Sanofi	12	$8,689
Lilly USA, LLC	14	$3,037
Novartis	38	$2,563
AstraZeneca(2 entities)	7	$1,261
Bristol Myers Squibb	14	$1,136
Astellas Pharma US Inc	4	$259
Eisai Inc.	12	$257
Johnson & Johnson(2 entities)	10	$201
Pfizer	10	$186
EMD Serono, Inc.	4	$185
Incyte Corporation	3	$148
Exelixis Inc.	7	$135
ASD Specialty Healthcare, LLC	2	$120
Pharmacyclics LLC, An Abbvie Company	2	$112
Merck	6	$110
GSK	6	$109
AbbVie	5	$108
Karyopharm Therapeutics Inc.	4	$94
Genmab U.S., Inc.	3	$91
Genentech USA, Inc.	4	$85
Regeneron Healthcare Solutions, Inc.	4	$78
Stemline Therapeutics Inc.	3	$74
Daiichi Sankyo Inc.	4	$73
ADC Therapeutics America, Inc.	3	$68
G1 Therapeutics, Inc.	3	$65
Sobi, Inc	3	$61
Taiho Oncology, Inc.	1	$49
Gilead(2 entities)	3	$47
Alnylam Pharmaceuticals Inc.	2	$47
Cumberland Pharmaceuticals, Inc.	3	$45
Kyowa Kirin, Inc.	2	$41
Servier Pharmaceuticals LLC	2	$40
Foundation Medicine, Inc.	1	$39
Puma Biotechnology, Inc.	2	$36
Recordati_rare_diseases_inc.	2	$34
Epizyme, Inc.	2	$32
Jazz Pharmaceuticals Inc.	2	$29
Seagen Inc.	2	$28
Sun Pharmaceutical Industries Inc.	2	$26
Sumitomo Pharma America, Inc.	1	$24
Myovant Sciences Inc.	1	$24
Pharmaessentia USA Corporation	1	$21
Fennec Pharmaceuticals, Inc.	1	$20
Beigene USA, Inc.	1	$20
Biocon Biologics Inc	1	$20
Tempus AI, Inc	1	$20
Geron Corporation	1	$19
Tersera Therapeutics LLC	1	$19
Bayer	1	$19
Pharmacosmos Therapeutics Inc.	1	$18
Boehringer Ingelheim	1	$17
Array Biopharma Inc	1	$15
Adaptive Biotechnologies Corporation	1	$15
Macrogenics, Inc.	1	$13
Partner Therapeutics, Inc.	1	$11

How this compares

$497,904 in reported general payments places this provider in the 80th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$3,631,039

Medicare patients

1,117

Services billed

251,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Goldsboro

John PowderlyHuntersville$21.2M
Kimberly BlackwellDurham$13.2M
Joshua ZeidnerChapel Hill$11.2M
Shelbi AtrashCharlotte$9.5M
Matthew WieduwiltWinston Salem$9.5M
Danielle BranderDurham$8.6M
Jared WeissChapel Hill$7.3M
Michael MorseDurham$6M
Autumn McReeChapel Hill$5.5M
Darla LilesGreenville$4.8M

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →